A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Carboplatin (Primary) ; MEDI 5752 (Primary) ; Pemetrexed (Primary) ; Durvalumab; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors MedImmune
- 08 Feb 2019 Planned End Date changed from 27 Mar 2023 to 16 Feb 2023.
- 08 Feb 2019 Planned primary completion date changed from 27 Mar 2023 to 16 Feb 2023.
- 31 Oct 2018 Planned End Date changed from 7 Feb 2023 to 27 Mar 2023.